Shen Jiayan, Zang Shoumei, Yu Xiaokai, Zhao Feng, Jiang Peng, Zhong Baishu, Zhou Hua, Yan Senxiang
Department of Radiation Oncology.
Department of Urology.
Medicine (Baltimore). 2019 Jul;98(27):e16351. doi: 10.1097/MD.0000000000016351.
How to manage patients with prostate cancer (PCa) with biochemical recurrence (BCR) following primary curative treatment is a controversial issue. Multiple disciplinary team (MDT) mechanism may propose an appropriate treatment plan for patients and can effectively improve patient prognosis and survival, reduce patient diagnosis and treatment waiting time, and greatly improve patient satisfaction.
Here, we presented a case of a 77-year-old man with a persistently elevated serum level of prostate-specific antigen (PSA), who had a history of radical prostatectomy (RP) and of 9 years endocrine therapy.
Castration-resistant prostate cancer and locally recurrent prostate cancer.
Androgen-deprivation therapy was first utilized 2 months after RP, due to the consideration of BCR on May 5, 2007. And during the next 9 years, he was treated with different endocrine agents but failed to maintain serum levels of PSA stable. Finally, the MDT suggested patient to perform salvage radiation therapy (SRT). Under MDT mechanism, we avoid secondary surgery, so as to reduce the patients' mental suffering and cost of patient care.
EPIC26 scale assessment revealed leak-free urine, good urine control, no defecation abnormalities or blood in the stool, no breast tenderness and breast enlargement significantly improved. The patient now has no adjuvant therapy, including endocrine therapy. The patient achieved good prognosis through local RT.
Pelvic SRT for patients with locally recurrent PCa may restore the same radical effect as RP. And more importantly, MDT mechanism plays an important role in making the most appropriate decisions for patients.
对于原发性根治性治疗后出现生化复发(BCR)的前列腺癌(PCa)患者,如何进行管理是一个存在争议的问题。多学科团队(MDT)机制可为患者提出合适的治疗方案,能有效改善患者预后和生存率,减少患者诊断和治疗等待时间,并极大提高患者满意度。
在此,我们介绍了一例77岁男性患者,其血清前列腺特异性抗原(PSA)水平持续升高,有根治性前列腺切除术(RP)病史及9年内分泌治疗史。
去势抵抗性前列腺癌和局部复发性前列腺癌。
由于考虑到2007年5月5日出现BCR,RP术后2个月首次采用雄激素剥夺治疗。在接下来的9年里,他接受了不同的内分泌药物治疗,但未能维持PSA血清水平稳定。最后,MDT建议患者进行挽救性放射治疗(SRT)。在MDT机制下,我们避免了二次手术,从而减轻了患者的精神痛苦和医疗护理成本。
EPIC26量表评估显示无尿漏、控尿良好、无排便异常或便血、无乳房压痛且乳房增大明显改善。患者目前无需辅助治疗,包括内分泌治疗。患者通过局部放疗获得了良好的预后。
对于局部复发性PCa患者,盆腔SRT可能恢复与RP相同的根治效果。更重要的是,MDT机制在为患者做出最合适的决策中发挥着重要作用。